Phaseline

Targets › ABAT

ABAT (4-aminobutyrate aminotransferase, mitochondrial): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2028.

Catalyzes the conversion of gamma-aminobutyrate and L-beta-aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively. Can also convert delta-aminovalerate and beta-alanine (By similarity). (UniProt, P80404)

Open in Phaseline: the race on ABAT, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Katarzyna KotulskaVigabatrin
Gamma-amino-N-butyrate transaminase inhibitor
ABATPhase 2Tuberous Sclerosis ComplexDec 2028

Conditions

Tuberous Sclerosis Complex (1)

Modalities

small molecule (1)

Companies

Katarzyna Kotulska (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.